Skip to main content
Skip to content
Case File
efta-02278091DOJ Data Set 11Other

EFTA02278091

Date
Unknown
Source
DOJ Data Set 11
Reference
efta-02278091
Pages
3
Persons
0
Integrity

Summary

Ask AI About This Document

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
To: Richard Kahn From: Lesley Groff Subject ThuWWI PM Re: I I Thx Sent from my iPhone On Jan 17, 2019, at 3:50 PM, Richard Kahn <richardkahn I 2@smail.com> wrote: i will mention to jee when we speak next thanks Richard Kahn HBRK Associates Inc. 575 Lexington Avenue 4th Floor New York, NY 10022 On Jan 17, 2019, at 12:19 PM, Lesley Groff wrote: requested I forward you the below 'catch up' email. <150636543')123blobjpg> EFTA_R1_01093672 EFTA02278091 — Fo From: To: jeevacationCWnrr <am Sent: Wednesday, January 16. 2019, 11:22:06 PM EST Subject: Catching Up Dear Jeffrey I hope you've been well. I wanted to update you on what I've been up to for the last two years. I was also hoping to talk with you to see if I might use the foundation's Lexington office conference room from time to time for my work and what I could provide in exchange for that. I am cc'ing Rich because I'm not sure if you still use this email? Since working for your foundation, I continued to publish as a journalist writing mostly about genetic vectors (Newsweek, Techonomy etc). I then set up an LLC that provides business development for labs that have reversed age- driven or degenerative diseases. Most of the therapies are genetic vectors, and have to show remarkable results at the mouse level and beyond. Regenerative medicine is a rapidly evolving field, and one that forces the medical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the ncuroglobin gene) under formal licence review with a publicly traded pharma group here in the US. And I am collaborating with a lab at the University of Pittsburgh that has reversed cirrhosis/ end stage liver disease in rats using the master transcription gene in hepatocytes. The concept of the latter gene vector is really intriguing in that a master transcription gene completely restored liver function by rebalancing genetic expression and thus proteostasis. While I don't really need an office at this point, I do need access to a conference room from time to time and it would be hugely helpful if I could access the foundation's. If there was some work that I could do for the foundation in exchange, I would be delighted to do that. EFTA_R1_0 1093673 EFTA02278092 It would be wonderful to catch up with you as well. all the best, <1506365439123b1ob.jpg> <1506365439123blobjpg><1506365439123blobjpg> EFTA_R1_01093674 EFTA02278093

Technical Artifacts (4)

View in Artifacts Browser

Email addresses, URLs, phone numbers, and other technical indicators extracted from this document.

Email2@smail.com
Phone2278091
Phone2278092
Phone2278093

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.

Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.